Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seagen Inc.
Bristol-Myers Squibb
Pfizer
Children's Cancer Group, China
Hoffmann-La Roche
City of Hope Medical Center